Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
77 hedge funds and large institutions have $120M invested in Adverum Biotechnologies in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 12 closing their positions.
229% more call options, than puts
Call options by funds: $276K | Put options by funds: $84K
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
13% more funds holding
Funds holding: 68 → 77 (+9)
2% more capital invested
Capital invested by funds: $118M → $120M (+$2.46M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 20
4.63% less ownership
Funds ownership: 86.07% → 81.45% (-4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$2.24M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.19M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.02M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$783K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$763K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.32M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.92M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$2.86M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.17M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.01M |
ADVM Hedge Fund Activity: Q3 2024 in Review
77 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2024, worth a combined $120M — up 2.1% from $118M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ADVM positions and 12 closed out — a net gain of 9 holders — while 19 added to existing stakes and 20 trimmed.
The largest buyer was Pale Fire Capital SE, opening a new position worth an estimated $2.24M. The largest seller was Assenagon Asset Management, cutting an estimated $4.32M.
- 77 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2024, up from 68 in Q2 2024.
- Funds reported $120M of Adverum Biotechnologies stock for Q3 2024, up 2.1% quarter-over-quarter.
- 21 funds opened new Adverum Biotechnologies positions in Q3 2024 and 12 closed out, a net change of +9 holders.
- The largest Adverum Biotechnologies buyer in Q3 2024 was Pale Fire Capital SE, an estimated $2.24M added.
- The largest Adverum Biotechnologies seller in Q3 2024 was Assenagon Asset Management, an estimated $4.32M sold.
Based on aggregated 13F filings for Q3 2024.